The Efficacy and Safety of Dolutegravir-based Dual Therapies in HIV-infected Patients With Intolerance or Toxicity to Nucleoside Analogues
Phase of Trial: Phase IV
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Dolutegravir (Primary) ; Cobicistat; Darunavir
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms DOLBI
- 13 Nov 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 13 Nov 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
- 27 Oct 2017 Results (n=53) presented at the 16th European AIDS Conference